演題詳細

ポスター / Poster

ポスター 49 (Poster 49) :ウイルス感染症

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F エメラルドABCD)
座長・司会
古川 雄祐 (Yusuke Furukawa):1
1:自治医科大学分子病態治療研究センター 幹細胞制御研究部
 
前へ戻る

The efficacy of entecavir in patients with hepatitis B virus reactivation after allo-HSCT

演題番号 : PS-1-374

吉岡 康介 (Kosuke Yoshioka):1、木村 公則 (Kiminori Kimura):2、山本 圭太 (Keita Yamamoto):1、金政 佑典 (Yusuke Kanemasa):1、成川 研介 (Kensuke Narukawa):1、石田 信也 (Shinya Ishida):1、五十嵐 愛子 (Aiko Igarashi):1、押川 学 (Gaku Oshikawa):1、小林 武 (Takeshi Kobayashi):1、土岐 典子 (Noriko Doki):1、垣花 和彦 (Kazuhiko Kakihana):1、大橋 一輝 (Kazuteru Ohashi):1、坂巻 壽 (Hisashi Sakamaki):1

1:Hematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan、2:Hepatology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan

 

Background: Reactivation of resolved hepatitis B virus (HBV) infection is a significant clinical problem. It has been unknown incidence, characteristic, and therapy of HBV reactivation in allogenic hematopoietic stem cell transplantation (allo-HSCT) recipients. To examine whether the efficacy and safety of entecavir (ETV) as first-line therapy for HBV reactivation following allo-HSCT we monitored serum ALT activity and HBV DNA levels in four patients.Methods: We retrospectively analyzed 313 patients who had undergone allo-HSCT at Tokyo Metropolitan Komagome Hospital between January 2007 and March 2012 to investigate incidence and characteristics of HBV reactivation. Clinical outcome, biochemical and virological factors, including HBV DNA level were studied after ETV treatment.Results: Among the 109 patients with resolved HBV infection before transplant, 4 (3.7%) patients have developed HBV reactivation. A median age of them was 51.5 (39-60), and half of them were male. The baseline disease included ALL (n=2) and MDS (n=2). No patient has developed either acute GVHD grade 2-4 or chronic GVHD. All of them have been treated with ETV, which induced suppression of HBV and rapid clinical improvement without side effects.Conclusions: ETV seems to be effective and safe treatment for HBV reactivation and monitoring of serum HBV DNA might be useful to screening with the onset of reactivation. We should be careful of incidence with HBV reactivation after allo-HSCT.

前へ戻る